NordForsk has decided to fund four postdoctoral research fellowships for young researchers in Denmark and Sweden within the Nordic Neutron Science Programme. The projects will receive a total of 6 million NOK.
The key breakthrough we aim to accomplish in this project is based on specific advantages of graphene: i) its ability to physically penetrate the bacterial biofilm, and ii) its ability to serve as a loading point for large amounts of hydrophobic drugs.
The innovative cell design is set to provide essential benefits to a broad range of research areas that rely on neutron studies of complex interfaces such as biological membrane science, antibiotic research and several topics in soft matter and polymer science. Specifically, within this project, two science cases will be addressed to validate the benefits of the novel sample environment.
The RAS-TOOLS project will pave the way for the development of next generation RAS monitoring for better control of water quality and fish health issues, and thereby contribute to the development of a sustainable RAS industry.
How has Sweden handled ethical issues during the COVID-19 pandemic? Göran Collste, Professor Emeritus of Applied Ethics at Linköping University, comments on some of the topics that were discussed at yesterday’s webinar.
Five Nordic research projects on COVID-19 are now being launched. The projects will take advantage of the Nordic countries’ unique health data to advance the knowledge base about COVID-19 for the benefit of the Nordic region and the entire world.
The generated evidence is expected to have high significance for patients, healthcare professionals and policymakers with an impact on recommendation how to handle Covid-19 in specific patient groups, for protecting vulnerable populations, for recommendations on medication use and for follow-up of patients surviving severe Covid-19 to treat complications.
Combining results from the three Scandinavian countries will strengthen our ability to study severe COVID-19 illness, susceptible subgroups and non-frequent outcomes.
